FDA approves Alcon steroid

December 3, 2007

The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.

The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.

Triesence injectable suspension, the active ingredient of which is triamcinolone acetonide, is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, in addition to being used for visualization during vitrectomy.